SCHEMBL6314864

SCHEMBL6314864

CCCCNC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.45
GAA P10253 4/20 0.43
HTT P42858 2/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 4/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
RECQL P46063 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.38
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316873 0.97 MAOB (0.44) MAOBGAAHTTTSHRHPGD
SCHEMBL6318968 0.96 MAOB (0.43) MAOBGAAHTTTSHRHPGD
SCHEMBL6316311 0.96 MAOB (0.43) MAOBGAAHTTTSHRHPGD
SCHEMBL6321222 0.96 MAOB (0.43) MAOBGAAHTTTSHRHPGD
SCHEMBL6319017 0.92 MAOB (0.41) MAOBGAATSHRHPGDSMN1; SMN2
SCHEMBL6318953 0.89 MAOB (0.38) MAOBGAATSHRCYP1A2CYP3A4
SCHEMBL6318234 0.88 L3MBTL1 (0.52) GAAHTTTSHRHPGDRAB9A
SCHEMBL6316190 0.87 L3MBTL1 (0.48) TSHRHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL6317244 0.87 KDM4E (0.40) MAOBGAAHTTTSHRHPGD
SCHEMBL6318971 0.86 TSHR (0.41) MAOBGAAHTTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAOB 1851/4885GAA 789/4885HTT 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.